Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Chelsea Therapeutics submits additional information on Northera NDA

Aug. 19, 2013

Cedars-Sinai begins phase I trial of Copaxone as immunization for Alzheimer's disease

Aug. 16, 2013

Taisho Pharmaceutical presents new mGlu2 receptor antagonists

Aug. 16, 2013

GW Pharmaceuticals opens U.S. IND application for phase III Sativex program

Aug. 16, 2013

Myelin Repair Foundation and Gencia Corporation to collaborate on multiple sclerosis therapeutics

Aug. 16, 2013

Methoxyflurane trial meets primary and secondary endpoints

Aug. 14, 2013

Lundbeck divulges novel PDE9 inhibitors for neurodegenerative disorders

Aug. 14, 2013

Zebrafish model mimics human affective disorders

Aug. 14, 2013

EnVivo Pharmaceuticals synthesizes new gamma-secretase modulators

Aug. 13, 2013

Spinifex Pharmaceuticals designs novel angiotensin AT2 receptor antagonists

Aug. 13, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...